# Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

> **NCT00006391** · PHASE1 · COMPLETED · sponsor: **NYU Langone Health**

## Conditions studied

- Fallopian Tube Cancer
- Ovarian Cancer
- Peritoneal Cavity Cancer

## Interventions

- **DRUG:** oxaliplatin
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00006391
- **Lead sponsor:** NYU Langone Health
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-08
- **Primary completion:** 2004-11
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2011-04-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006391, "Oxaliplatin and Topotecan in Treating Patients With Previously Treated Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT00006391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*